Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.S Bio, a cancer therapeutics company, has completed a $26 million series B financing led by Bio One Capital and new investor Aravis Venture. Additional new investors included the Lacuna Apo BioTech Fund advised by Adamant Biomedical Investments and Zurcher Kantonalbank.
Subscribe to our email newsletter
S Bio will utilize the proceeds to primarily fund the development efforts of its two lead compounds, SB939, a HDAC inhibitor, and SB1518, a JAK 2 inhibitor, both in Phase I clinical trials.
Jan-Anders Karlsson, CEO of S Bio, said: “As part of the financing, we would like to welcome Jean-Philippe Tripet, managing partner of Aravis to our board of directors. Mr Tripet, with his extensive knowledge and experience in the life sciences arena, is a valuable addition to the board.
“This financing round is recognition of the progress we have made in rapidly and effectively developing our compounds. We look forward to having our lead compounds tested in Singapore, US and other international trial sites and advancing them further into Phase II development.”